Gamaleya Research Institute

What Gamaleya Research Institute does

The Gamaleya Research Institute (Federal State Budgetary Institution "National Research Center for Epidemiology and Microbiology named after Honorary Academician N.F. Gamaleya" of the Ministry of Health of the Russian Federation) is a federal government research institution founded in 1891 and headquartered in Moscow. It conducts research in epidemiology, medical and molecular microbiology, infectious disease immunology, and virology, and is designated as a WHO Collaborating Center. The institute maintains approximately 98 scientific staff and operates a five-program postgraduate (aspirantura) training pipeline across Virology, Microbiology, Infectious Diseases, Immunology, and Epidemiology, enrolling 50 students annually.

The institute's core technology platform is its proprietary adenoviral vector system, refined continuously since the 1980s, which underpins its registered vaccine portfolio. The portfolio includes Sputnik V (Gam-COVID-Vac), the world's first registered COVID-19 vaccine (registration certificate LP-006395, August 11, 2020), two Ebola vaccines registered in 2015 with a third in 2020 and an international patent granted in 2017–2018, plus pipeline candidates for MERS, influenza, pertussis, cancer (oncology vaccines under 2025 public disclosure), and Flortiazinone (an antibiotic candidate against multi-drug-resistant bacteria). The institute holds 58 Russian patents and is credited with approximately 1,450 VAK-recommended publications.

Commercially, the institute is structured as a state budgetary institution. Its revenues derive primarily from Ministry of Health state assignments, vaccine licensing and distribution partnerships (notably with Petrovax Pharm for production and distribution), modest postgraduate tuition (1,577.7 thousand rubles federal, 360 thousand rubles other sources), and international cooperation contracts (e.g., 2019 agreement with France's Foundation for Influenza Epidemiology, plus prior Guinea clinical trials). Its customer base is concentrated on the Russian Ministry of Health as principal domestic buyer, foreign governments for trial participation, and postgraduate aspirants. Operating presence is anchored in Moscow (ul. Gamalei, dom 18), with the "Medgamal" branch as a wholly-owned R&D division and a joint Department of Infectology and Virology with Sechenov First Moscow State Medical University.

Name

Gamaleya Research Institute

Legal name

Federal State Budgetary Institution "National Research Center for Epidemiology and Microbiology named after Honorary Academician N.F. Gamaleya" of the Ministry of Health of the Russian Federation (Федеральное государственное бюджетное учреждение «Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи» Министерства здравоохранения Российской Федерации)

Website

https://gamaleya.org

Company type

Private

Founded year

1891

Operating status

Operating

Headcount range

101–250 employees

Short description

Gamaleya Research Institute is a Russian federal government research center, founded in 1891, that develops vaccines using proprietary adenoviral vector technology — including Sputnik V (the first registered COVID-19 vaccine) and Ebola vaccines — and operates under the Ministry of Health of the Russian Federation, also offering postgraduate scientific training in five specialties.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Vaccines

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens) (HLAAAEAC)

akta.pro secondary industries

Clinical Development & Regulatory for Vaccines (trials, pharmacovigilance, lot release) (HLAAAEAK), Pandemic Preparedness & Rapid-Response Vaccines (HLAIAEAF), Immunization & Vaccine Delivery Programs (BPADAIAB)

Keywords

• Vaccine development
• Adenoviral vector technology
• Infectious disease research
• Epidemiology and microbiology
• Postgraduate biomedical education

Headquarters

HQ city

Moscow

HQ country

Russia

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Infrastructure

Revenue model

1. Government Research Funding: As a Federal State Budgetary Institution (FGBu) under the Russian Ministry of Health, the institute receives government funding for research activities conducted under the State Assignment (Gosudarstvennoye zadaniye) of the Ministry of Health.
2. Vaccine Development and Licensing: Development and registration of vaccines with licensing agreements with pharmaceutical companies such as Petrovax Pharm for production and distribution.
3. Educational Services: Postgraduate education (aspirantura) programs generating revenue through tuition fees. Financial data shows 1577.7 thousand rubles from federal budget and 360 thousand rubles from other sources for educational activities.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

The Gamaleya Research Institute develops, registers, and licenses vaccines against infectious diseases using proprietary adenoviral vector technology refined since the 1980s, including Sputnik V (COVID-19), Ebola, MERS, influenza, and pertussis vaccines, plus a cancer vaccine candidate and the Flortiazinone antibiotic compound. It also delivers postgraduate (aspirantura) scientific training in Virology, Microbiology, Infectious Diseases, Immunology, and Epidemiology (50 annual positions), and operates a joint Department of Infectology and Virology with Sechenov First Moscow State Medical University.

Product overview

The National Research Center for Epidemiology and Microbiology named after N.F. Gamaleya (НИЦЭМ им. Н.Ф. Гамалеи) is a leading research institution founded in 1891, operating under the Russian Ministry of Health. The center's product portfolio centers on vaccine development using proprietary adenoviral vector technology developed since the 1980s. Core products include registered vaccines against COVID-19 (Sputnik V, registered August 2020 with certificate ЛП-006395), Ebola fever (two vaccines registered in 2015, third in 2020), as well as vaccine candidates for MERS, influenza, and pertussis. The center is also developing an oncology vaccine. Additionally, the center offers educational services through a postgraduate (aspirantura) program in five specialties: Virology, Microbiology, Infectious Diseases, Immunology, and Epidemiology, with a total capacity of 50 students across all programs. The center's research infrastructure includes specialized departments and laboratories, an Institute of Virology, a branch called Medgamал, and a Museum of History.

Differentiator

Problem solved

Functional benefit

Products and services

• Sputnik V COVID-19 Vaccine (Вакцина против COVID-19) The first registered COVID-19 vaccine in Russia, developed using heterologous prime-boost adenoviral vector technology. Registration certificate ЛП-006395 issued August 11, 2020 by the Russian Ministry of Health.
• Ebola Vaccine (Вакцина против лихорадки Эбола) Two Ebola vaccines developed using adenovirus-based vectors, registered in Russia in 2015; a third vaccine registered in 2020. Phase III trials in Guinea included approximately 2,000 recipients. International patent obtained 2017-2018.
• MERS Vaccine Candidate (Вакцина против MERS) Vaccine candidate development for Middle East Respiratory Syndrome (MERS) using adenoviral vector technology.
• Influenza Vaccine (Вакцина против гриппа) Vaccine development research for influenza prevention.
• Pertussis (Whooping Cough) Vaccine (Вакцина от коклюша) Vaccine development research for whooping cough (pertussis) prevention.
• Cancer / Oncological Vaccine (Вакцина против рака) Oncology vaccine research and development, with coverage in medical publications (Medical Gazette, August 2025).
• Flortiazinone (Фтортиазинон) Pharmaceutical drug candidate developed by the center, described as suppressing bacteria with multiple drug resistance.
• Postgraduate (Aspirantura) Programs — five specialties Full-time postgraduate education across five specialties (Virology, Microbiology, Infectious Diseases, Immunology, Epidemiology) totaling 50 admitted positions annually, leading to dissertation defense in the institute's dissertation councils.
• Department of Infectology and Virology (Кафедра инфектологии и вирусологии) Educational department jointly operated with Sechenov First Moscow State Medical University for teaching infectology and virology.

Quantifiable outcome

• First registered COVID-19 vaccine in the world (August 2020)
• +4 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Partnerships

Two partnerships are on record, tiered minor and core.

• Foundation for Influenza Epidemiology (France)minorStrategic or Co-development Partner · 1 December 2019International cooperation agreement signed on December 1, 2019, for influenza epidemiology research collaboration. The agreement was set to expire on December 31, 2020. No renewal information available in current sources.
• Petrovax PharmcoreTechnology or IntegrationStrategic partnership for vaccine production and distribution. Director academician A.L. Gintsburg and Petrovax Pharm president M. Tsyferov have conducted joint interviews discussing vaccine development and production collaboration.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Market position

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Gamaleya Research Institute